Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
|Articles|September 16, 2008
- June30 2003
- Volume 10
- Issue 12
SAVINGS PLANS LOSE OUT
Author(s)Michael Sheehan
Advertisement
Among the first casualties of thebattle over President Bush's taxreforms were proposals for sweepingchanges in tax-advantaged savingsaccounts. The plan was to simplifya dizzying array of IRAs, RothIRAs, and other types of accountsinto a couple of basic plans: aLifetime Savings Account, a kind ofsuper Roth IRA, and a RetirementSavings Account. Insiders note thatthe plan was developed under formerUS Treasury Secretary PaulO'Neill, with little input from theWhite House. After drawing firefrom a number of sectors, includingfinancial services and benefits consultingfirms that stood to lose businessif the new accounts were enacted,the Bush administration hasbacked off from these savingsreforms, at least for this year.
Articles in this issue
about 18 years ago
Time to Invest Your Cash for Retirementabout 18 years ago
What You Need to Know to Retire Earlyabout 18 years ago
Incorporate the New Rules of Retirementabout 18 years ago
Swiss Annuities Tower the American Fundsabout 18 years ago
Second Home Helps Fund Retirementabout 18 years ago
Redesign Your Practice's Retirement Plan?about 18 years ago
Smart Home-Buyingabout 18 years ago
"Retirement": You Can Quote Me on Thatabout 18 years ago
401(K)s AND REAL ESTATEabout 18 years ago
WATCH ESTATE PLANAdvertisement
Related to this article
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Asundexian Safely Reduces Ischemic Stroke Risk Regardless of Infarct Patterns on MRI
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5